HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 15 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
MOCS2
molybdenum cofactor synthesis 2
Chromosome 5 Β· 5q11.2
NCBI Gene: 4338Ensembl: ENSG00000164172.21HGNC: HGNC:7193UniProt: O96007
44PubMed Papers
21Diseases
0Drugs
50Pathogenic Variants
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
molybdopterin synthase activityprotein bindingMo-molybdopterin cofactor biosynthetic processcytosolsulfite oxidase deficiency due to molybdenum cofactor deficiency type Bsulfite oxidase deficiency due to molybdenum cofactor deficiencyencephalopathy due to sulfite oxidase deficiencysulfite oxidase deficiency due to molybdenum cofactor deficiency type A
✦AI Summary

MOCS2 encodes two protein subunits (MOCS2A and MOCS2B) through a bicistronic transcript with overlapping reading frames, functioning as essential components of the molybdopterin synthase complex 12. This complex catalyzes the conversion of precursor Z into molybdopterin by mediating the incorporation of two sulfur atoms to generate a dithiolene group, which is crucial for molybdenum cofactor (MoCo) biosynthesis 1. MOCS2A serves as a sulfur donor after being thiocarboxylated at its C-terminus, while MOCS2B transfers the sulfur to precursor Z to form molybdopterin 1. MoCo is required for the activity of molybdoenzymes including sulfite oxidase, xanthine dehydrogenase, and aldehyde oxidase 3. Pathogenic variants in MOCS2 cause molybdenum cofactor deficiency type B, characterized by neonatal-onset seizures, feeding difficulties, delayed motor development, and progressive neurological damage 43. The disease typically leads to early childhood death due to sulfite toxicity from deficient sulfite oxidase activity 56. Unlike type A deficiency, no effective substitution therapy currently exists for MOCS2-related deficiency, though rare mild cases with later onset and better prognosis have been reported 7.

Sources cited
1
MOCS2 encodes molybdopterin synthase subunits through bicistronic transcript and catalyzes molybdopterin formation
PMID: 10053004
2
MOCS2 has bicistronic architecture with overlapping reading frames encoding two subunits
PMID: 10746556
3
MOCS2 mutations cause type B MoCD affecting all molybdoenzymes
PMID: 21031595
4
MOCS2 mutations cause neonatal seizures, feeding difficulties, and delayed motor development
PMID: 31201073
5
MoCD leads to early childhood death due to neurological damage from sulfite oxidase deficiency
PMID: 12754701
6
No specific treatment exists for MoCD type B unlike type A
PMID: 36296488
7
Mild cases of MOCS2-related MoCD with later onset and better prognosis exist
PMID: 39695700
Disease Associationsβ“˜21
sulfite oxidase deficiency due to molybdenum cofactor deficiency type BOpen Targets
0.81Strong
sulfite oxidase deficiency due to molybdenum cofactor deficiencyOpen Targets
0.67Moderate
encephalopathy due to sulfite oxidase deficiencyOpen Targets
0.56Moderate
sulfite oxidase deficiency due to molybdenum cofactor deficiency type AOpen Targets
0.46Moderate
liver diseaseOpen Targets
0.35Weak
acneOpen Targets
0.32Weak
hair anomalyOpen Targets
0.27Weak
anorexia nervosaOpen Targets
0.27Weak
autism spectrum disorderOpen Targets
0.27Weak
obsessive-compulsive disorderOpen Targets
0.27Weak
schizophreniaOpen Targets
0.27Weak
attention deficit hyperactivity disorderOpen Targets
0.27Weak
bipolar disorderOpen Targets
0.27Weak
major depressive disorderOpen Targets
0.27Weak
Tourette syndromeOpen Targets
0.27Weak
Abnormality of metabolism/homeostasisOpen Targets
0.27Weak
glomerulonephritisOpen Targets
0.27Weak
skin appendage disorderOpen Targets
0.22Weak
alcohol drinkingOpen Targets
0.20Weak
genetic disorderOpen Targets
0.19Weak
Molybdenum cofactor deficiency BUniProt
Pathogenic Variants50
NM_176806.4(MOCS2):c.16C>T (p.Gln6Ter)Pathogenic
Sulfite oxidase deficiency due to molybdenum cofactor deficiency type B1|Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A|not provided
β˜…β˜…β˜†β˜†2026β†’ Residue 6
NM_004531.5(MOCS2):c.65dup (p.Leu23fs)Pathogenic
Sulfite oxidase deficiency due to molybdenum cofactor deficiency type B1|not provided
β˜…β˜…β˜†β˜†2026β†’ Residue 23
NM_004531.5(MOCS2):c.567A>C (p.Ter189Tyr)Pathogenic
Sulfite oxidase deficiency due to molybdenum cofactor deficiency type B1|not provided
β˜…β˜…β˜†β˜†2026β†’ Residue 189
NM_004531.5(MOCS2):c.539_540del (p.Lys180fs)Likely pathogenic
Sulfite oxidase deficiency due to molybdenum cofactor deficiency type B1|not provided|Abnormality of metabolism/homeostasis
β˜…β˜…β˜†β˜†2026β†’ Residue 180
NM_004531.5(MOCS2):c.346_349del (p.Val116fs)Pathogenic
Sulfite oxidase deficiency due to molybdenum cofactor deficiency type B1|not provided
β˜…β˜…β˜†β˜†2026β†’ Residue 116
NM_004531.5(MOCS2):c.106_107del (p.Met36fs)Pathogenic
not provided|Sulfite oxidase deficiency due to molybdenum cofactor deficiency type B1
β˜…β˜…β˜†β˜†2025β†’ Residue 36
NM_004531.5(MOCS2):c.377+1G>APathogenic
not provided
β˜…β˜…β˜†β˜†2025
NM_176806.4(MOCS2):c.88C>T (p.Gln30Ter)Pathogenic
not provided|Sulfite oxidase deficiency due to molybdenum cofactor deficiency type B1|Combined molybdoflavoprotein enzyme deficiency
β˜…β˜…β˜†β˜†2025β†’ Residue 30
NM_176806.4(MOCS2):c.1A>G (p.Met1Val)Pathogenic
not provided|Sulfite oxidase deficiency due to molybdenum cofactor deficiency type B1
β˜…β˜…β˜†β˜†2024β†’ Residue 1
NM_004531.5(MOCS2):c.304G>T (p.Glu102Ter)Pathogenic
not provided|Combined molybdoflavoprotein enzyme deficiency
β˜…β˜…β˜†β˜†2024β†’ Residue 102
NM_176806.4(MOCS2):c.33T>G (p.Tyr11Ter)Pathogenic
Sulfite oxidase deficiency due to molybdenum cofactor deficiency type B1|Combined molybdoflavoprotein enzyme deficiency|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 11
NM_004531.5(MOCS2):c.99-2A>GLikely pathogenic
not provided|Combined molybdoflavoprotein enzyme deficiency
β˜…β˜…β˜†β˜†2024
NM_004531.5(MOCS2):c.164C>G (p.Ser55Ter)Pathogenic
not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 55
NM_176806.4(MOCS2):c.114G>A (p.Trp38Ter)Likely pathogenic
not provided|Sulfite oxidase deficiency due to molybdenum cofactor deficiency type B1
β˜…β˜…β˜†β˜†2024β†’ Residue 38
NM_004531.5(MOCS2):c.182_185del (p.Gln61fs)Pathogenic
Sulfite oxidase deficiency due to molybdenum cofactor deficiency type B1|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 61
NM_004531.5(MOCS2):c.469dup (p.Thr157fs)Pathogenic
not provided|Sulfite oxidase deficiency due to molybdenum cofactor deficiency type B1
β˜…β˜…β˜†β˜†2024β†’ Residue 157
NM_004531.5(MOCS2):c.118G>T (p.Glu40Ter)Pathogenic
not provided|Sulfite oxidase deficiency due to molybdenum cofactor deficiency type B1
β˜…β˜…β˜†β˜†2024β†’ Residue 40
NM_176806.4(MOCS2):c.3G>A (p.Met1Ile)Pathogenic
Sulfite oxidase deficiency due to molybdenum cofactor deficiency type B1|not provided
β˜…β˜…β˜†β˜†2023β†’ Residue 1
NM_176806.4(MOCS2):c.30_34del (p.Leu10fs)Likely pathogenic
Sulfite oxidase deficiency due to molybdenum cofactor deficiency type B1
β˜…β˜…β˜†β˜†2020β†’ Residue 10
NM_176806.4(MOCS2):c.68C>G (p.Ser23Ter)Pathogenic
not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 23
View on ClinVar β†—
Related Genes
MOCOSShared pathway100%AOX1Protein interaction100%SAE1Protein interaction100%MTARC2Protein interaction100%TSTProtein interaction100%MPSTProtein interaction99%
Tissue Expression6 tissues
Heart
100%
Liver
70%
Brain
64%
Ovary
32%
Lung
23%
Bone Marrow
16%
Gene Interaction Network
Click a node to explore
MOCS2MOCOSAOX1SAE1MTARC2TSTMPST
PROTEIN STRUCTURE
Preparing viewer…
PDB5MPO Β· 2.43 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
1.07LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.64 [0.40–1.07]
RankingsWhere MOCS2 stands among ~20K protein-coding genes
  • #9,617of 20,598
    Most Researched44
  • #1,342of 5,498
    Most Pathogenic Variants50 Β· top quartile
  • #10,748of 17,882
    Most Constrained (LOEUF)1.07
Genes detectedMOCS2
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
Beyond Moco Biosynthesis-Moonlighting Roles of MoaE and MOCS2.
PMID: 35744859
Molecules Β· 2022
1.00
2
Mutations in the molybdenum cofactor biosynthetic genes MOCS1, MOCS2, and GEPH.
PMID: 12754701
Hum Mutat Β· 2003
0.90
3
The Clinical and Molecular Characteristics of Molybdenum Cofactor Deficiency Due to MOCS2 Mutations.
PMID: 31201073
Pediatr Neurol Β· 2019
0.80
4
Molybdenum cofactor deficiency: Mutations in GPHN, MOCS1, and MOCS2.
PMID: 21031595
Hum Mutat Β· 2011
0.70
5
Molybdenum Cofactor Deficiency in Humans.
PMID: 36296488
Molecules Β· 2022
0.60